The ongoing genericization of Yaz in the United States as well as the adverse effects of the health system reforms in various countries were the main reason for this development. Yaz sales were down 7%, mainly due to the generic competition in the U.S. as I already mentioned. Outside the U.S., the Yaz family of products advanced by 8%The entire transcript can be found at Seeking Alpha
Women’s health, yes, it’s correct. We’re, of course, under pressure especially in the oral contraceptive field especially now also in Europe. In the U.S., as you know, (inaudible). We do have plans and you know that we have a number of lifecycle management activities in this field, be it our patch for example that we are developing, the Flex system that we developed.
And you can be rest-assured that we will continue to invest in this field and look for new opportunities to capitalize on the market leadership that we have in the contraceptive field. What exactly will happen over the next two to three years, I would like to ask you to give us little bit more time to elaborate on that. But we have not written off the franchise at all.
But as Yaz trial attorneys we are seeing a much different picture. Doctors who previously prescribed Yaz have testified that they no longer voluntarily write prescriptions for the drug, and one of our treating doctors actually now requires women to sign a waiver if they insist on a Yaz Rx. That is because they now recognize the greater risk from Yaz, with no corresponding benefit. The reduction in sales of Yaz has, in part, been a result of the recognition by women's health care advocates that Yaz presents unacceptable increased risks for women.
Yaz has always been about one thing, increased profits for Bayer and increased risks for women.
If you are one of the women who has suffered injury at the expense of increased profits for Bayer, you need information. Contact the drug and medical device advocates for safety at Zoll, Kranz and Borgess by contacting Anneke Kurt toll-free at 888.841.9623 or via email at Anneke@toledolaw.com. You can also visit our website by clicking here.